Aclarion, Inc. Share Price

ACON

US6551874091

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 25/09/2026 BST			5-day change	1st Jan Change
2.590 ^USD	-1.52%		+2.78%	-43.70%

08-20	Aclarion Adds University Of Arizona College Of Medicine ? Phoenix As Clarity Trial Site	CI
08-12	Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process	CI

Analysts' recommendations: Aclarion, Inc.

06/07/22

Maxim Starts Aclarion at Buy With $3 Price Target

More recommendations

Press Releases: Aclarion, Inc.

08-20	Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site	AQ
08-12	Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process	AQ
08-04	Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology	AQ
07-29	Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026	AQ
07-21	Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice	AQ

More press releases

Managers and Directors: Aclarion, Inc.

Manager	Title	Age	Since
Brent Ness CEO	Chief Executive Officer	59	14/09/2021
Gregory Gould DFI	Director of Finance/CFO	60	01/09/2025
Daniel Keefe PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
William Wesemann BRD	Director/Board Member	69	31/12/2015
David Neal BRD	Director/Board Member	55	31/08/2016
Jeffrey Thramann CHM	Chairman	61	20/04/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACLARION, INC.	-1.52%	+2.78%	-67.75%	-99.99%	7.47M
LONZA GROUP AG	-0.14%	+4.33%	+9.88%	+31.73%	47.97B
IQVIA HOLDINGS INC.	-1.69%	+1.48%	+53.02%	+33.59%	44.5B
REVOLUTION MEDICINES, INC.	+2.56%	+7.34%	+382.17%	+594.81%	43.93B
BEONE MEDICINES AG	+0.24%	+2.85%	+9.78%	+89.54%	41.03B
CELLTRION, INC.	-0.62%	-1.11%	+4.70%	+46.02%	29.85B
MEDPACE HOLDINGS, INC.	-0.28%	+1.07%	+26.83%	+152.91%	17.27B
EUROFINS SCIENTIFIC SE	-0.46%	+1.20%	+26.78%	+41.32%	15.3B
ASCENDIS PHARMA A/S	-2.21%	-4.70%	-	-	14.82B
TEMPUS AI, INC.	+3.37%	+9.21%	+9.93%	-	15.34B
Average	-0.08%	+2.40%	+50.59%	+111.24%	27B
Weighted average by Cap.	+0.11%	+2.86%	+83.03%	+156.20%

See all sector performances

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
25/09/26	US$2.590	-1.52%	30,137
24/09/26	US$2.630	-10.54%	61,389
23/09/26	US$2.940	+11.79%	309,151
22/09/26	US$2.630	+6.91%	33,928
21/09/26	US$2.460	-2.38%	12,410

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.590USD

Average target price

7.500USD

Spread / Average Target

+189.58%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	7.47M 6.55M 6.19M 5.64M 10.55M 716M 10.63M 74.04M 28.68M 366M 28.03M 27.42M 1.17B	P/E 2026 *	-0.57x	P/E 2027 *	-0.47x
Enterprise Value	7.47M 6.55M 6.19M 5.64M 10.55M 716M 10.63M 74.04M 28.68M 366M 28.03M 27.42M 1.17B	EV / Sales 2026 *	55.3x	EV / Sales 2027 *	29x
Free-Float	76.02%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	ACON	Delayed
CBOE	ACON	Real-time
Deutsche Boerse AG	IT20	Delayed
Tradegate	IT20	Real-time

08-20	Aclarion Adds University Of Arizona College Of Medicine ? Phoenix As Clarity Trial Site	CI
08-12	Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process	CI
08-06	Aclarion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Tranche Update on Aclarion, Inc.'s Equity Buyback Plan announced on April 22, 2026.	CI
08-04	Aclarion, Inc Announces Nociscan Now Available At Goodman Campbell Brain & Spine At Ascension St. Vincent	CI
07-07	Aclarion Announces Texas Spine Care Center as New CLARITY Site	CI
06-09	Aclarion Launches Market Access Program With PRIA Healthcare	MT
06-08	Echo Lake Capital cancelled the acquisition of Aclarion, Inc..	CI
06-08	Aclarion Rejects Echo Lake Capital's Acquisition Proposal	MT
06-01	Aclarion Demonstrates Potential Clinical Applications Of Nociscan Beyond Surgical Decision Support In New Immune-Biomarker Study	CI
05-28	Aclarion says board to review Echo Lake Capital's acquisition proposal	RE
05-27	Echo Lake Capital proposed to acquire Aclarion, Inc..	CI
05-13	Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

1 day	-1.52%
1 week	+2.78%
Current month	+10.21%
1 month	+4.02%
3 months	-4.43%
6 months	-19.81%
Current year	-43.70%

1 week	2.46	2.96
1 month	2.25	2.96
Current year	1.95	9.36
1 year	1.95	12.03
3 years	1.95	89,552.67
5 years	1.95	586,115.57
10 years	1.95	586,115.57

Aclarion, Inc. Share Price

Stocks

ACON

US6551874091

Biotechnology & Medical Research

Valuation: Aclarion, Inc.

Chart: Aclarion, Inc.

Latest news: Aclarion, Inc.

Analysts' recommendations: Aclarion, Inc.

Press Releases: Aclarion, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Aclarion, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/08/26	Amanda Sequira	Buy	Director	5,857	0.2379%
14/08/26	Gregory Gould	Buy	Chief Financial Officer	10,000	0.4061%
13/08/26	David Neal	Buy	Director	7,500	0.3046%

	2026 *	2027 *
Net sales	135K 118K 112K 102K 191K 12.94M 192K 1.34M 519K 6.61M 507K 496K 21.24M	257K 226K 213K 194K 363K 24.63M 366K 2.55M 987K 12.58M 965K 944K 40.44M
Net income	-10.71M -9.4M -8.87M -8.09M -15.14M -1.03B -15.25M -106M -41.13M -524M -40.2M -39.33M -1.69B	-13.47M -11.82M -11.16M -10.17M -19.04M -1.29B -19.18M -134M -51.73M -659M -50.56M -49.47M -2.12B
Net Debt	-	-